Rank #1500RAPT

RAPT Therapeutics, Inc.

$57.80

0.10% (Daily)

Market Cap

$1.67B

Revenue

$N/A

Rank by MCap

#1500

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Brian Russell Wong M.D., Ph.D.

Headquarters

South San Francisco, CA

Employees

About RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It...